Taking the question as asked, rather than the general version of it. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.

PeptideChemSF said:

Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c…

Agreed, and reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.

I would rather be corrected than agreed with, if it comes to it.

MikeKY_noInsulin said:

I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something…

Can confirm the pattern MikeKY_noInsulin describes. A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.

That is the short version; the long version is somebody else's post.

Clinical perspective, offered as context rather than as advice.

Shot day Wednesday report relevant to baseline bloodwork:

Week 29. Currently on 1.0mg. Down 75 lbs from starting weight of 287 lbs.

This week's observations: Mild fatigue day 1-2 post-injection, then fine.

Labs due next week — looking forward to seeing the metabolic panel. I'll post results in the Lab Results section when they come in.